Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8830987 | 1.00 | MMP2 (0.49) | MMP2ANPEPPOLBFKBP1ANPSR1 | |
| SCHEMBL15399060 | 1.00 | MMP2 (0.49) | MMP2ANPEPPOLBFKBP1ANPSR1 | |
| SCHEMBL7734259 | 1.00 | MMP2 (0.49) | MMP2ANPEPPOLBFKBP1ANPSR1 | |
| SCHEMBL9521198 | 0.90 | POLB (0.48) | POLBPREPRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9428692 | 0.89 | MMP2 (0.50) | MMP2ANPEPPOLBNPSR1HTT | |
| SCHEMBL7805540 | 0.89 | MMP2 (0.50) | MMP2ANPEPPOLBNPSR1HTT | |
| SCHEMBL24065124 | 0.89 | POLB (0.43) | MMP2ANPEPPOLBFKBP1ANPSR1 | |
| SCHEMBL7149261 | 0.89 | POLB (0.43) | MMP2ANPEPPOLBPTPN1 | |
| SCHEMBL2999647 | 0.88 | POLB (0.49) | MMP2POLBFKBP1ANPSR1MAPT | |
| SCHEMBL9098331 | 0.88 | POLB (0.49) | MMP2POLBFKBP1ANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230121086-A1 | RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4089079-A1 | ROR GAMMA T INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| EP-4089080-A1 | RORyT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| US-20220308043-A1 | FLUORESCENT PROBES FOR IDENTIFICATION AND QUANTIFICATION OF HEPATIC TRANSPORTERS IN VITRO AND IN VIVO | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-09-29 | — | — | US | disclosed |
| CN-108026049-B | Compositions and methods for treating and preventing neurodegenerative disorders | 阿尔泽恩股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| WO-2021139595-A1 | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 东莞市东阳光新药研发有限公司 | 2021-07-15 | — | — | WO | disclosed |
| US-8809359-B2 | Phenyl amino pyrimidine bicyclic compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2014000032-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2014-01-03 | — | — | WO | disclosed |
| US-20140005161-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2014-01-02 | — | — | US | disclosed |
| WO-2011092671-A1 | PROLINE DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | disclosed |
| EP-0646595-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1998-11-04 | — | — | EP | disclosed |
| US-5623049-A | FLEXIBLE ANTISENSE AGENTS COMPRISING OLIGONUCEOTIDES HAVING THE (DEOXY)RIBOSE BACKBONE REPLACED BY AN OLIGOPEPTIDE; PROTEASE- AND NUCLEASE-RESISTANT; VIRICIDES; ATTACHED TO CARRIERS ABLE TO PENETRATATE IN CELLS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| EP-0646595-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0272456-B1 | 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-31 | — | — | EP | disclosed |
| US-4822787-A | 3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid compounds and antimicrobial activity thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| EP-0272456-A1 | 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | MMP2 4643/4885ANPEP 4223/4885POLB 2581/4885 |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | MMP2 2585/4885ANPEP 1615/4885POLB 956/4885 |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | MMP2 2585/4885ANPEP 1615/4885POLB 956/4885 |
| US-20140005161-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | MMP2 4659/4885ANPEP 1876/4885POLB 1238/4885 |
| US-20220308043-A1 | FLUORESCENT PROBES FOR IDENTIFICATION AND QUANTIFICATION OF HEPATIC TRANSPORTERS IN VITRO AND IN VIVO | ABCB11, SLC10A1, SLC10A2 | MMP2 1180/4885ANPEP 1690/4885POLB 3442/4885 |
| US-20230121086-A1 | RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | MMP2 4373/4885ANPEP 4130/4885POLB 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.